Total Payments
$56,048
2024 Payments
$10,545
Companies
13
Transactions
35
Medicare Patients
736
Medicare Billing
$138,204
Payment Breakdown by Category
Consulting$34,739 (62.0%)
Research$13,070 (23.3%)
Other$6,640 (11.8%)
Travel$1,058 (1.9%)
Food & Beverage$530.04 (0.9%)
Education$12.04 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $34,739 | 14 | 62.0% |
| Unspecified | $13,070 | 6 | 23.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,120 | 5 | 7.4% |
| Honoraria | $2,520 | 1 | 4.5% |
| Travel and Lodging | $1,058 | 4 | 1.9% |
| Food and Beverage | $530.04 | 4 | 0.9% |
| Education | $12.04 | 1 | 0.0% |
Payments by Type
General
$42,978
29 transactions
Research
$13,070
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $26,404 | 16 | $0 (2024) |
| EMD Serono, Inc. | $12,825 | 3 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $5,480 | 1 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $4,040 | 4 | $0 (2021) |
| Aveo Pharmaceuticals, Inc. | $2,238 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,672 | 2 | $0 (2023) |
| Ares Trading SA | $1,425 | 1 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $900.00 | 1 | $0 (2019) |
| Eli Lilly and Company | $862.50 | 1 | $0 (2021) |
| Roche Products Limited | $105.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,545 | 6 | PFIZER INC. ($7,120) |
| 2023 | $16,436 | 6 | EMD Serono, Inc. ($12,825) |
| 2022 | $2,520 | 1 | PFIZER INC. ($2,520) |
| 2021 | $6,403 | 6 | Janssen Scientific Affairs, LLC ($4,040) |
| 2020 | $3,200 | 1 | PFIZER INC. ($3,200) |
| 2019 | $10,347 | 6 | AstraZeneca Pharmaceuticals LP ($5,480) |
| 2018 | $6,517 | 7 | PFIZER INC. ($6,412) |
| 2017 | $82.04 | 2 | E.R. Squibb & Sons, L.L.C. ($70.00) |
All Payment Transactions
35 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $630.00 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,890.00 | General |
| Category: ONCOLOGY | ||||||
| 06/26/2024 | PFIZER INC. | LORBRENA (Drug), XALKORI, MEKTOVI | — | In-kind items and services | $1,400.00 | Research |
| Study: LORLATINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 04/12/2024 | Aveo Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: TBD - WCT/AVEO | ||||||
| 03/12/2024 | PFIZER INC. | BRAFTOVI (Drug), VIZIMPRO, MEKTOVI | — | In-kind items and services | $3,200.00 | Research |
| Study: ENCORAFENIB DACOMITINIB BINIMETINIB MULTI PRODUCT LORLATINIB CRIZOTINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/01/2024 | Ares Trading SA | — | Consulting Fee | Cash or cash equivalent | $1,425.00 | General |
| 11/27/2023 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,800.00 | General |
| 08/18/2023 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,800.00 | General |
| 07/20/2023 | PFIZER INC. | VIZIMPRO (Drug), MEKTOVI, XALKORI | — | In-kind items and services | $3,200.00 | Research |
| Study: DACOMITINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/11/2023 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,225.00 | General |
| 06/04/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $172.35 | General |
| 06/01/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $238.18 | General |
| Category: Oncology | ||||||
| 06/10/2022 | PFIZER INC. | LORBRENA (Drug) | Honoraria | Cash or cash equivalent | $2,520.00 | General |
| Category: ONCOLOGY | ||||||
| 05/19/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $862.50 | General |
| 05/05/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 03/25/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 03/25/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 03/25/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 03/25/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 08/07/2020 | PFIZER INC. | LORBRENA (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: LORLATINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/24/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $5,480.00 | General |
| Category: Oncology | ||||||
| 09/17/2019 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Oncology | ||||||
| 07/15/2019 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $3,456.39 | General |
| 06/13/2019 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $166.00 | General |
| 05/23/2019 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LORLATINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,600 | 2 |
| DACOMITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ENCORAFENIB DACOMITINIB BINIMETINIB MULTI PRODUCT LORLATINIB CRIZOTINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| TBD - WCT/AVEO | Aveo Pharmaceuticals, Inc. | $2,000 | 1 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS 986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | E.R. Squibb & Sons, L.L.C. | $70.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 156 | 285 | $68,395 | $27,267 |
| 2022 | 4 | 182 | 410 | $91,995 | $36,410 |
| 2021 | 5 | 235 | 563 | $120,255 | $50,289 |
| 2020 | 4 | 163 | 338 | $73,500 | $24,237 |
Total Patients
736
Total Services
1,596
Medicare Billing
$138,204
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 85 | 166 | $33,200 | $12,528 | 37.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 48 | 96 | $24,960 | $11,258 | 45.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 23 | 23 | $10,235 | $3,482 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 99 | 267 | $53,400 | $20,097 | 37.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 43 | 103 | $26,780 | $12,157 | 45.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 21 | 21 | $9,345 | $3,246 | 34.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 19 | 19 | $2,470 | $910.02 | 36.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 117 | 394 | $78,800 | $32,162 | 40.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 50 | 88 | $22,880 | $11,017 | 48.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 25 | 25 | $11,125 | $3,954 | 35.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 32 | 42 | $5,460 | $2,306 | 42.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 14 | $1,990 | $850.64 | 42.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 80 | 239 | $47,800 | $15,699 | 32.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 30 | 30 | $13,350 | $4,408 | 33.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 21 | 26 | $6,760 | $2,316 | 34.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 32 | 43 | $5,590 | $1,815 | 32.5% |
About Dr. Jessica Bauman, M.D
Dr. Jessica Bauman, M.D is a Medical Oncology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2008. The National Provider Identifier (NPI) number assigned to this provider is 1619139235.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jessica Bauman, M.D has received a total of $56,048 in payments from pharmaceutical and medical device companies, with $10,545 received in 2024. These payments were reported across 35 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($34,739).
As a Medicare-enrolled provider, Bauman has provided services to 736 Medicare beneficiaries, totaling 1,596 services with total Medicare billing of $138,204. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Philadelphia, PA
- Active Since 06/25/2008
- Last Updated 06/16/2015
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1619139235
Products in Payments
- LORBRENA (Drug) $15,490
- TAGRISSO (Drug) $5,480
- BRAFTOVI (Drug) $3,200
- VIZIMPRO (Drug) $3,200
- Vitrakvi (Drug) $900.00
- FOTIVDA (Drug) $238.18
- TECENTRIQ (Biological) $105.00
- Rubraca (Drug) $14.51
- ALUNBRIG (Drug) $12.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Philadelphia
Daniel Haller, Md, MD
Medical Oncology — Payments: $744,976
Medical Oncology $744,976
Adam Cohen, Md, MD
Medical Oncology — Payments: $302,018
Medical Oncology $302,018
Dr. Jean-Pierre Issa, M.d, M.D
Medical Oncology — Payments: $223,097
Medical Oncology $223,097
Alexander Perl, Md, MD
Medical Oncology — Payments: $218,549
Medical Oncology $218,549
Carl June, Md, MD
Medical Oncology — Payments: $140,824
Medical Oncology $140,824
Anthony Olszanski, M.d, M.D
Medical Oncology — Payments: $131,641
Medical Oncology $131,641